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Abstract
In this chapter, the authors will discuss the epidemiology and clinical presenta-
tions of amyloidosis. The main body of this chapter will concentrate on treatment 
options, both FDA-approved and experimental, specific to the various forms of 
amyloidosis. Since this set of diseases can affect multiple organ systems, we tackle 
the therapeutic avenues and the current challenges in each system under clinical 
investigation, including neurological, psychiatric, gastrointestinal, cardiovas-
cular, endocrine, renal and hematologic, in addition to options for palliative 
treatment for severe symptom management and improved quality of life. Several 
recent groundbreaking discoveries have opened up the potential for successful 
treatment of peripheral and central neurological amyloidoses making this an 
exciting and evolving field.
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1. Epidemiology
Amyloidosis is a rare, albeit likely underdiagnosed, disorder [1]. Claims data 
in the United States shows prevalence of amyloid light-chain (AL) amyloidosis 
increased between 2007 and 2015 from 15.5 to 45 cases per million [2]. Incidence 
did not significantly increase over this time period, but ranged from 9.7 to 14 cases 
per million-person years [2]. This equates to more than 12,000 people in the US 
currently living with this disorder. Older data, from 1950 to 1989, found 9 cases per 
million people, more evidence of an increasing prevalence over time [3]. The trend 
in age- and sex-adjusted incidence rate of amyloidosis per million person years from 
1950 to 1989 was not found to be significant (Figure 1).
This phenomenon could be explained by increased detection and diagnosis. 
Studies in the United Kingdom and Sweden demonstrated a prevalence of 20 cases 
per million and incidence of 5 cases per million-person years, 3 of them being AL, 
and 1 amyloid A (AA) amyloidosis [1, 4]. A US study found a mean age at diagnosis 
of AL amyloidosis of 63 with a standard deviation of 12, 55% male [2]. International 
studies also show that men are slightly more likely to be diagnosed with AL, 
however, AA amyloidosis more commonly affects women, possibly due to higher 
prevalence of underlying rheumatoid arthritis [1].
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AL amyloidosis is more prevalent than AA amyloidosis in developed countries, 
however, in developing countries and some Mediterranean countries, AA is more 
prevalent (Figure 2). Other studies have shown AL to be more prevalent than AA in 
developed countries, but in developing nations AA has a higher prevalence than AL [1].
This follows the logic of the epidemiologic transition, since as a country devel-
ops, diseases transition from infectious to chronic disease states. In developing 
nations, endemic infections such as tuberculosis or leprosy lead to AA amyloidosis, 
Figure 1. 
Age- and sex-adjusted average annual incidence rates of amyloidosis per million person-years in Olmsted 
County, Minnesota from 1950 to 1989.
Figure 2. 
Mortality of amyloidosis subtypes UK from 2000 to 2020,008 (n = 903).
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while in developed nations chronic diseases lead to AL amyloidosis. The exception 
to this is Mediterranean nations, while developed, have a higher prevalence of 
AA amyloidosis. This is likely due to relatively high prevalence autoinflammatory 
diseases such as familial Mediterranean fever. For example, in Spain, AL amyloido-
sis has become the most prevalent subtype, increasing in frequency relative to other 
subtypes from 21% in 1977 to 44% in 2013 [5].
The prognosis for amyloidosis varies by subtype, treatment modality, extent of 
cardiac involvement and, to a lesser degree, hepatic and autonomic involvement 
[1]. A Swedish study estimated median survival to be 3, 4, and 6 years for AL, AA, 
and localized amyloidosis [6]. In regards to systemic amyloidosis, a median survival 
time of 32 months was seen in the UK [4]. Older studies found untreated median 
survival time ranging from 6 months to 4 years [1].
2. Palliative treatments for amyloidosis
The protein deposition and accumulation inherent in amyloidosis causes a wide 
range of systemic symptoms, and patients may also suffer from side effects of cura-
tive therapies. Though many mistakenly believe palliative interventions are only for 
end of life care, palliative treatments can be implemented at any stage of illness, and 
may help curb severe symptoms. In many forms of cancer, early palliative interven-
tions have been shown to increase quality of life for both patients and caregivers 
[7]. While no studies have been conducted to evaluate the effectiveness of palliative 
therapies on amyloidosis specifically, palliative treatments for many of the common 
sequelae of amyloidosis have been well researched [8].
2.1 Pain
Neuropathic pain (NP) is the most common pain sensation reported in people 
with amyloidosis. NP is notoriously difficult to control, and is often not responsive 
to typical pain regimens. Antidepressants, anticonvulsants, opioids, and topical 
medications are the most common pharmacologic agents used. Unfortunately, many 
of these agents have their own side effects, and should be used with caution [8].
2.2 Depression
There has long been a link noted between depression and dementia, and depres-
sion has been viewed as both a prodrome and a risk factor for dementia. About half 
of patients with late-onset depression are found to have cognitive impairment, and 
the prevalence of dementia in depression has been reported between 9 and 68% 
[9]. A past history of depression is a known risk factor for developing Alzheimer’s 
disease and vascular dementia, even when the episode of depression occurred over 
10 years prior. Rather than a prodrome, depression seems to be a risk factor for 
Alzheimer’s disease, as evidenced by a neuropathological study showing increased 
neurofibrillary tangles and plaques in the hippocampus in those with a history 
of depression [10]. Depression is linked to hypercortisolemia, which may cause 
prolonged damage to the hippocampus. Depression may also be a psychological 
reaction to the diagnosis of cognitive impairment, and may even reveal previ-
ously clinically silent cognitive impairment by depleting cognitive reserve [11]. 
Additionally, the use of tricyclic antidepressants in the elderly may also contribute 
to clinical dementia due to their anticholinergic effects.
The link between depression and Alzheimer disease may involve mechanisms 
in the metabolism of β-amyloid peptides in the brain. A recent study has shown 
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significant associations between geriatric depression and β-amyloid peptide deposits 
in the insula, hippocampus, and amygdale [12]. Another recent study showed the link 
between hereditary gelsolin amyloidosis (AGel) and neuropsychiatric changes. The 
gelsolin mutation is associated with cerebrovascular fragility, and is an autosomal 
dominant form of systemic amyloidosis. The study found visuoconstructional dif-
ficulties in the AGel group in both the block design and drawing tasks. While overall 
processing speed was similar in both groups, the AGel group produced more errors 
[13]. The behavioral and psychological symptoms of people with dementia result in 
greater cognitive and functional impairment, and are associated with greater amyloid 
deposition in the neurodegenerative process leading to Alzheimer’s disease [14].
2.3 Sexual dysfunction
The pathophysiology of sexual dysfunction in amyloidosis can range from 
medication side effects (corticosteroids, opioids), to primary hypogonadism 
(amyloid deposition in the testes), and depression. Determining the etiology of 
sexual dysfunction is key in selecting the proper treatment. For erectile dysfunc-
tion, sildenafil has been shown to be effective. Testosterone replacement may help 
in cases of hypogonadism, but has not been studied in patients with amyloidosis.
3. Renal amyloidosis
Renal amyloidosis is often the major cause of death for individuals with AL, AA, 
and hereditary amyloidosis; untreated, it usually progresses to end-stage renal 
disease. Understanding how amyloid fibrils form, and how the renal amyloidosis 
manifests are crucial in determining treatment approaches specific to each type of 
amyloidosis.
While amyloid can be found anywhere in the kidney, it often predominates in 
the glomerulus, forming nodules composed of amyloid protein that disrupt glo-
merular function. Consequently, patients with renal amyloidosis present with the 
components of nephrotic syndrome: severe proteinuria, hypoalbuminemia, edema, 
decreased GFR. When the amyloid protein is in the tubulointerstitium or vascula-
ture, the patient will instead demonstrate minimal proteinuria with a decrease in 
GFR. (Vascular involvement may also come with HTN.) Generally, renal impair-
ment progresses more rapidly with glomerular involvement. Patients mostly present 
with normal-sized kidneys but amyloidosis can cause enlargement of the kidneys.
Of the three main categories of renal amyloidoses, AL remains the most com-
mon, accounting for 81 and 68% of amyloidosis cases in two recent studies from 
the U.S. and Italy [15, 16]. In 50% of patients with systemic Ig-related amyloidosis, 
kidney disease presents as the most common manifestation [17].
3.1 Renal AL amyloidosis
Because AL amyloidosis is commonly associated with an underlying plasma cell 
dyscrasia, the purpose of treatment is to destroy amyloid-producing plasma cells. 
Therefore, treating AL amyloidosis is based on anti-myeloma therapy, which must 
be tailored to each patient’s age, comorbidities, extent of organ involvement, and 
patient’s wishes. The standard treatment was repeated cycles of oral melphalan 
and prednisone with an increase in median survival to 1.5 years [18]; however, this 
has changed in the past decade. In an 8 year longitudinal study by [19], 25–50% of 
patients who underwent high-dose intravenous melphalan followed by autologous 
stem cell transplantation(HDM/SCT to support bone marrow recovery demonstrated 
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complete hematologic responses. In 2006, Seldin et al. followed 43 patients who 
received HDM/SCT between 1994 and 1996, and found that median survival 
rate of 10 years for patients with a complete hematologic response [20]. In 2011, 
Sanchorawala et al. followed the long-term outcome of 421 patients and reported a 
long-term survival of up to 20 years [19]. More research is being done on the effective-
ness of repeated HDM/SCT treatments, some of them reporting favorable outcomes 
in patients who did not achieve a complete hematologic response the first time.
Despite the success of HDM/SCT, treatment-associated mortality is 12–14% 
with a higher prevalence in those with cardiac amyloidosis. Because stem cell 
mobilization requires high doses of growth factors, this can be complicated in 
patients with nephrotic syndrome or heart failure due to fluid retention. In addition 
to increased risks for splenic rupture (especially in patients with splenic amyloid), 
thrombocytopenia, and neutropenia, patients may also be subject to acute renal 
failure as reported by two different studies [21]. The British Journal of Hematology 
published guidelines in 2014 for HDM/SCT as first line treatment for selected 
patients up to 60–75 years of age with eGFR >50 ml/min, low cardiac biomarkers, 
low level plasma cell infiltration in the bone marrow, and lacking the following 
contraindications: cardiac amyloidosis, severe autonomic neuropathy, significant 
GI bleeding due to amyloid, advanced renal failure, age over 7 years, symptomatic 
recurrent amyloid related pleural effusions [22].
As an alternative to HDM/SCT, a combination of oral melphalan and high dose 
dexamethasone was shown by Pallidini et al. to have a 33% complete hematologic 
response in patients who are ineligible for HDM/SCT [23]. In addition to the oral 
melphalan and dexamethasone, patients can use proteasome inhibitor-based 
regimens and a bortezomib-alkylator-steroid combination for a rapid response [22].
3.2 Renal AA amyloidosis
Because AA amyloidosis is often associated with the production of serum 
amyloid A (SAA), an acute phase reactant protein from an underlying inflamma-
tory disease, the goal of treatment is to treat the cause. Stopping the inflammatory 
processes of familial Mediterranean fever (FMF), rheumatoid arthritis (RA), and 
other causes of AA has been shown by several studies to prevent amyloidosis. For 
example, colchicine is used to inhibit Familial Mediterranean Fever-associated 
inflammation, which prevented amyloidosis production [24]. In a 2002 study, 
Elkyam et al. treated a patient with infliximab for rheumatoid arthritis, whose pro-
teinuria resolved [25]. It is thought that these agents have additional anti-amyloid 
effects by suppressing cytokine production or by altering expression of specific 
mediators of cellular toxicity [26].
A new treatment approach involving fibrillogenic inhibition is currently under-
way, involving eprosidate, a sulfonated, negatively charged molecule like heparan 
sulfate. The molecule competitively binds to glycosaminoglycan-binding sites on 
SAA, and inhibits fibril polymerization and amyloid deposition. In a multicenter, 
randomized, double-blind, placebo controlled trial, Dember et al. demonstrated that 
eprodisate slowed the decline of renal function in AA amyloidosis patients [27]. The 
results from the second Phase III study will help determine whether eprosidate will 
become one of the new treatment approaches in fighting renal AA amyloidosis [28].
3.3 Dialysis and kidney transplantation
For patients with renal amyloidosis who are in ESRD, dialysis or kidney trans-
plantation is other options. Currently, the literature for dialysis differs for AL amy-
loidosis patients and AA amyloidosis patients, but the consensus is a poor prognosis 
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Figure 3. 
AL amyloidosis organ involvement pattern in patients with multiple myeloma.
for AL amyloidosis patients on dialysis, especially those with cardiac involvement. 
For AA amyloidosis patients on dialysis, Guillaume et al. reported a 15% mortal-
ity rate, a better prognosis overall [29]. Treating patients who are on dialysis with 
HDM/SCT has shown no difference between the hematologic response rate and 
treatment -associated mortality are similar in dialysis-dependent patients compared 
with the overall population of patients who undergo this treatment [27].
Kidney transplantation is a good option for patients who have a complete hema-
tologic response in AL amyloidosis and do not have significant extrarenal disease. 
In 2012, Gurusu et al. examined survival rates of 44 patients with amyloidosis who 
had undergone kidney transplantation and found the same outcomes with patients 
with other kidney diseases [30]. This indicates that amyloidosis patients should be 
accepted as transplant candidates.
3.4 Bortezomib, a game changer for multiple myeloma and AL amyloidosis
Monoclonal antibody therapy has become a mainstay of treatment in plasma 
cell disorders such as multiple myeloma and primary systemic (AL) amyloidosis. 
Bortezomib (Velcade), a proteasome inhibitor, has shown effectiveness as an initial 
therapy of multiple myeloma in stem cell transplant (SCT) eligible patients [31, 32]. 
Bortezomib has been especially effective in younger patients and contributed sig-
nificantly to improvements in survival seen in the early 2000s [33]. Bortezomib and 
other proteasome inhibitors are associated with less cardiotoxic risk than chemo-
therapeutics such as melphalan, cyclophosphamide, and doxorubicin [34]. Modern 
induction therapy for multiple myeloma now consists a combination of bortezomib 
and dexamethasone (BD), plus thalidomide or melphalan for both transplant-
eligible and SCT ineligible patients. A phase IIIB study found no difference in 
outcomes or survival between BD, BD plus thalidomide, or BD plus melphalan in 
transplant-ineligible patients [35]. Bortezomib is also effective as a consolidation 
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and maintenance therapy, prolonging progression-free survival and overall survival 
in patients with partial or very good partial response following induction/consoli-
dation therapy [36].
AL amyloidosis can present spontaneously or in association with other blood 
cell disorders such as multiple myeloma and lymphoplasmocytic lymphoma. AL 
amyloidosis is a well-recognized complication of multiple myeloma in particular, 
occurring in approximately 10–15% of patients (Figure 3) [37]. Not surprisingly, 
bortezomib therapy is now a recommended treatment for primary AL amyloidosis 
both in SCT ineligible patients and post SCT patients [38, 39]. Reece et al. showed 
bortezomib to be a particularly effective and well-tolerated therapy in relapsed AL 
amyloidosis patients, evidenced by once and twice-weekly treatments both effec-
tively inducing a hematological response in this population [40, 41]. A randomized 
phase III trial showed more profound and frequent hematological responses to 
bortezomib versus melphalan plus dexamethasone in patients with newly diagnosed 
AL amyloidosis, indicating bortezomib as a promising initial therapy [42].
4. Amyloidosis and the nervous system
Neurologic involvement of systemic amyloidosis has been observed in over 20% 
of cases, and the median duration of neuropathic symptoms prior to diagnosis is 
2 years [43]. The pathophysiology of amyloid deposition contributing to the clinical 
manifestation of neurodegenerative disorders, including Alzheimer’s Dementia, 
Parkinson’s Disease, and Huntington’s Disease, has been well-documented [44]. 
Furthermore, cerebral amyloid angiopathy is a well-known cause/risk factor for 
intracerebral hemorrhage in the elderly [45]. Lastly, systemic amyloidosis (clas-
sically, primary amyloidosis) affects not only the central nervous system, but is a 
well-known cause of peripheral and autonomic neuropathy [46]. Thus, the deposi-
tion of abnormally folded proteins has not only been linked to progressive and acute 
devastating CNS disorders, but also to neurologic sequelae throughout the body. 
In this section, we describe some of the novel treatments and their mechanisms of 
action for both CNS and PNS manifestations of the illness.
4.1 Amyloid beta: Alzheimer’s dementia, and cerebral amyloid angiopathy
There are no current therapies that modify the deposition of A beta amyloid 
in the CNS. Therefore the focus of treatment has been mainly symptomatic with 
acetylcholinesterase inhibitors, antidepressants and antipsychotics. However, new 
research focusing on monoclonal antibodies reducing plaque load prove to have 
promising results in the mice model [47]. Modest levels of peripherally administra-
tion antibodies against the amyloid beta-peptide crossed the blood brain barrier 
entering the CNS and inducing clearance of preexisting amyloid via activation of 
microglial cells [48]. Bapineuzumab, Solanezumab, Gantenerumab, Crenezumab, 
Ponezumab, BAN2401, and Aducaumab are anti-amyloid beta monoclonal antibod-
ies that have progressed to human trials and paved the pathway for the development 
of more effective therapies.
The mechanism of Bapineuzumab, one of the first humanized monoclonal IgG1 
antibody used in humans, attaches to soluble and fibrillar amyloid beta via the five 
N-terminal residues inducing Fc receptor-mediated microglial phagocytosis of amy-
loid beta deposits. In phase 1, 30 patients were divided into low dose (0.5 mg/kg), 
medium (1.5 mg/kg) and high dose (5 mg/kg), and overall the drug was considered 
to be safe. 3/10 participants in the high dose category developed MRI findings typical 
of vasogenic edema that eventually resolved. Amyloid-related imaging abnormalities 
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(ARIA) were coined to describe imaging abnormalities as a result of treatment, for 
example ARIA-H for microhemorrhage and hemosiderosis and ARIA-E for effusion 
or vasogenic edema. IV infusion in phase 2 of the trial showed no significant treat-
ment differences in patients with mild to moderate Alzheimer’s disease. A parallel 
phase 2, as well as retrospective study done by neuroradiologists resulted in the 
conclusion that there is an increased occurrence of ARIA-E in carriers of APOE4, 
necessitating the incorporation of biomarkers to qualify for treatment, but increased 
numbers of symptomatic ARIA-E resulted in discontinuation of bapineuzumab trials.
Solanezumab, another humanized IgG1 monoclonal antibody, completed 
phase 3 testing without meeting efficacy requirements. It binds the mid-domain of 
amyloid beta residues to increase clearance of monomers, and continues in pre-
clinical Alzheimer’s disease trials to see if there is a benefit to earlier intervention. 
Phases 1 and 2 showed a relationship between dose and CSF Amyloid-beta protein. 
In phase 3 studies, termed EXPEDITION 1 and EXPEDITION 2, 18 month trials of 
IV solanezumab 400 mg against IV placebo, did not demonstrate any significant 
benefit. However, it demonstrated the drugs favorable safety profile with only 0.9% 
incidence of ARIA-E compared to 0.4% seen in the placebo. A third phase 3 trial, 
EXPEDITION 3, also showed nonsignificant results with solanezumab and eventu-
ally led to the drug’s discontinuation for dementia.
As opposed to the previously mentioned therapies, Gantenerumab was the 
first fully human IgG1 antibody against the conformational epitope expressed 
on amyloid beta fibrils that contain both the N-terminal and central amino acids. 
Phase 1 trials with patients who had mild to moderate Alzheimer’s disease showed 
that seven IV infusions (60–200 mg) every 4 weeks reduced brain burden. It also 
showed the drug’s favorable safety profile. 2 out of 6 patients in the high dose group 
experienced ARIA-E. Initial phase 2 trials included 360 participants and doses of 
subcutaneous 105 mg or 225 mg every 4 weeks for 2 years, but was later expanded 
to a phase 2/3 with 799 participants showed no significant treatment effects for 
CDE-SB or changes in the amount of brain amyloid beta. Currently Gantenerumab, 
like solanezumab, is being explored for patients with fast progression and autoso-
mal dominant Alzheimer’s disease.
Other therapies that have proven to have non-significant results in the treat-
ment of amyloid beta deposition within the CNS include Crenezumab, Ponezumab, 
BAN2401, and Aducaumab. Despite these findings, the tolerability of monoclonal 
antibodies lends hope for developing therapies for this pathology. Moreover, future 
studies should focus on the importance of brain entry of anti-amyloid beta monoclo-
nal antibodies, as it is not currently clear whether therein lies any benefit as only 0.1% 
cross the blood brain barrier. Dosage and stage of disease are two other important 
points for consideration in improving the efficacy of these therapies, and whether the 
lack of efficacy was due to insufficient amounts of drug or late stage disease [49].
4.2 Transthyretin amyloidosis
Transthyretin is a liver-derived protein, that when misfolded can accumulate in 
the liver, kidney, GI tract, and the peripheral nerves. Multiple genetic abnormalities 
have been shown to contribute to increased predisposition and familial forms of 
transthyretin amyloidosis. These have led to syndromes such as familial amyloidotic 
cardiomyopathy and familial amyloidotic polyneuropathy [49, 50].
Familial amyloidotic polyneuropathy (FAP) is a fatal condition that is caused by 
the substitution of a methionine residue for a valine residue at the 30th position of 
the TTR gene [51]. In this section, we briefly discuss the role of liver transplantation 
and more thoroughly introduce the use of RNA interference molecules to decrease 
transthyretin production.
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5. Liver transplantation
Around 95% of transthyretin is produced by the liver, and thus, it was pos-
tulated that liver transplantation would provide great benefit for patients with 
transthyretin amyloidosis. The first liver transplantation for transthyretin amyloi-
dosis was done in 1990 in Sweden and showed promising results. Since then, liver 
transplantation has been a standard treatment for this devastating disorder [51].
Liver transplantation has been shown to be of benefit if intervention is taken 
earlier in the disease course. The risks and prognostic factors for liver transplanta-
tion have been well-documented, including the long wait times for an available 
transplantable organ. However, additional prognostic factors for survival post liver 
transplantation in patients with amyloidotic polyneuropathy include hereditary and 
geographic factors, duration of the disease, initial degree of polyneuropathy, pres-
ence of autonomic dysfunction, co-morbid cardiac, kidney/bladder, and GI impair-
ment, and prior nutritional status. Liver transplantation is usually not a procedure 
that will improve the patient’s condition, but rather, prevent further decline.
5.1 IDOX, doxycycline, and RNAi therapy
Since the difficulties associated with liver transplantation prevented adequate 
treatment of FAP patients, new non-surgical treatment methods were researched. 
It was initially shown that 4′iodo′4′-doxy-doxorubicin (IDOX) inhibits amyloid 
formation and promotes the resorption of amyloid deposits. Initially shown that 
IDOX can induce amyloid resorption in patients with immunoglobulin light chain 
amyloidosis, it was further studied for all types of amyloid deposition disorders. It is 
hypothesized that IDOX exerts its effects by inhibiting fibril growth and increasing 
the solubility of amyloid deposits. This, in turn, facilitates amyloid clearance. These 
results have been consistent in both in vivo and in vitro studies through two distinct 
binding sites between IDOX and amyloid fibrils [52].
At around the same time as IDOX was being investigated, Doxycycline became 
the next promising medication that showed similar success in both FAP transgenic 
mice and phase II human trials with transthyretin amyloidosis. It’s theorized mech-
anism of action involves amyloid fibril destructuration and promotion of amyloid 
deposition. In one phase II trial, doxycyclin plus tauroursodeoxycholic acid resulted 
in stable cardiac and neuropathy symptoms after 1 year of treatment. When used in 
conjunction with TTR stabilizers, therapy could both block formation and promote 
clearance of existing amyloid simultaneously [53, 54].
The most recent research for transthyretin amyloidosis treatment has sur-
rounded RNA interference (RNAi) therapy. RNAi therapy decreases transthyretin 
production from the liver by directly suppressing mRNA transcription of the 
gene that codes for the transthyretin protein. Due to the specific nature of this 
pharmacology, long-term side-effects of RNAi therapy have not been reported. 
Two medications, Patisiran and Inotersen, have become FDA approved in the past 
5 years after studies have shown a dose-dependent reduction of both mutant and 
nonmuntant tranthyretin production and deposition. This RNAi therapy has been 
shown to cause between 50 and 80% reduction in transthyretin levels as early as 
2–3 weeks after therapy initiation. Furthermore, these medications have provided 
significant neurologic symptomatic benefit in a majority of patients when com-
pared to placebo therapy. Since these medications affect both mutant and non-
mutant transthyretin production, they have been shown to not only have decreased 
side-effects to liver transplantation, but better long-term efficacy. The most com-
mon side effect to the medication reported has been transfusion-related reactions in 
8–20% of patients [49, 55, 56].
Amyloid Diseases
10
6. Cardiac amyloidosis
Along with the kidneys, the heart is one of the most commonly affected organs 
in cases of amyloidosis, as amyloid fibrils deposit in its parenchyma and impair it 
from functioning optimally. The deposition of either light chain amyloid (AL) or 
transthyretin (TTR) in the cardiac myocardium is responsible for the vast majority 
(>95%) of cases of amyloid cardiomyopathy [57]. This infiltration of the myocar-
dial tissue essentially results in a clinical presentation of heart failure with pre-
served ejection fraction; therefore, the treatment is twofold and is targeted at both 
the primary, underlying disease process and at the secondary heart failure.
6.1 AL amyloid
In regards to the primary disease, treatment varies substantially based on the 
nature of the abnormal protein that is deposited in the cardiac tissue. AL amyloid, 
or primary amyloid, affects the heart by depositing abnormally-folded proteins into 
the myocardium, rendering the ventricles concentrically thickened, thus impairing 
their ability to accommodate adequate filling volumes. Some studies suggest that 
the amyloidogenic proteins also have direct cytotoxic effects on the myocardial 
cells. The pathogenic proteins in AL amyloid are misfolded immunoglobulin light 
chains produced by a number of clonal plasma cells in the bone marrow; therefore, 
cytotoxic therapies against these cells have been proven to be effective. A combina-
tion of oral melphalan, dexamethasone, autologous stem cell transplantation and/
or bortezomib is often utilized and tailored to each individual case based on various 
factors such as age, stage of disease, and patient’s desire for treatment. These drug 
regimens are further discussed in the section on renal amyloidosis treatment.
6.2 TTR amyloid
In transthyretin amyloidosis, the protein transthyretin (TTR) loses stability, mis-
folds, and deposits in organs throughout the body, including the cardiac myocardium. 
In contrast to other types of amyloidosis, which may or may not involve the heart, 
TTR almost always features cardiac involvement and myocardial protein deposition. 
The consequences of protein deposition in the heart are essentially the same across all 
types of amyloidosis as the ventricles thicken and result in a restrictive type of cardio-
myopathy that prevents the heart from properly filling with blood during the diastolic 
phase of the cardiac cycle. The restrictive cardiomyopathy leads to a clinical picture 
of heart failure, with symptoms that often significantly decrease the patient’s quality 
of life. The most definitive treatment for TTR amyloidosis is liver transplantation. 
This is because the TTR protein is produced in the liver and eliminating the source of 
the protein would eliminate the pathogenic process altogether. Liver transplantation, 
however, may not be an option for patients who are not candidates for the procedure. 
This is where a recently studied drug, Tafamidis, plays a key role. Tafamidis is an 
agent that exhibits its therapeutic effect by stabilizing the TTR protein, thus prevent-
ing its misfolding and subsequent deposition in organs of the body. In a randomized, 
placebo-controlled, double blind study performed in September 2018, Tafamidis was 
found to improve the quality of life of amyloidosis patients by slowing the progres-
sion of the disease and reducing the functional impairment of affected nerves and 
systems throughout the body [58, 59]. Other drugs that also may be beneficial in TTR 
amyloidosis cases include an NSAID called Diflunisal, doxycycline, and an antisense 
therapy called ISIS-TTRrx. Both Diflunisal and doxycycline are thought to have the 
same mechanism of action as Tafamidis, as they stabilize the TTR protein and prevent 
amyloidogenesis. ISIS-TTRrx’s mechanism of action differs and works by directly 
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suppressing the gene that expresses the TTR protein. These agents are still being 
investigated for efficacy in experiments and clinical trials [59].
6.3 Heart failure
Heart failure secondary to cardiac amyloidosis is treated rather differently than 
heart failure that is organic or secondary to other causes. Agents that typically play 
key roles in heart failure management, such as beta blockers, ace inhibitors, and 
calcium channel blockers, are avoided and, sometimes, even contraindicated. These 
drugs are ineffective in cases of amyloid cardiomyopathy due to the pathophysiology 
of protein deposition rather than intrinsic cellular dysfunction of the cardiac cells. 
Utilization of calcium channel blockers, for example, results in an apparent amplifi-
cation of the drugs’ negative inotropic effects and a resultant decompensation of the 
amyloid cardiomyopathy [60, 61]. One class of drugs- the loop diuretics- remains the 
cornerstone medication utilized even in cases of heart failure due to amyloid cardio-
myopathy. A loop diuretic combined with an aldosterone antagonist has been found 
to be the most efficacious combination of treatment for amyloid-associated heart 
failure [57, 62]. Along with drug therapy, other vital lifestyle changes include salt and 
fluid restriction, as well as regular weight measurements to monitor volume status.
7. Amyloidosis of the respiratory tract
Amyloidosis is characterized by pathological misfolding of the amyloid pro-
tein and its deposition as fibrils leading to organ dysfunction. Amyloidosis of the 
respiratory tract can be localized or a part of a systemic picture of dysfunction. 
Pulmonary amyloidosis is only symptomatic if amyloid deposits are present on the 
alveoli, causing impaired gas exchange. Amyloid deposition in the lung parenchyma 
may manifest as nodular deposits or lead to localized lymphomas.
Tissue deposits of misfolded amyloid protein in the form of fibrils characterize 
systemic amyloidosis. There are 15 different kinds of systemic amyloidoses, defined 
based on the characteristics of the deposited amyloid protein [63]. The primary 
kinds of amyloidosis that impact the lungs are systemic AL and localized AL con-
sisting of monoclonal light chains, AA amyloid consisting of apolipoprotein serum 
amyloid A, and ATTRwt consisting of wild-type transthyretin [64]. Regardless 
of the type of amyloid fibril that is deposited, all fibrils have the same backbone 
structure that the Congo red stain binds in order to reveal an apple-green birefrin-
gence under polarized light [65]. Tissue biopsy is central to diagnosis of amyloidosis 
as treatment modalities vary based on the type of amyloid protein that is deposited. 
Less invasive procedures like abdominal fat biopsy and fine needle biopsy are 
indicated over more invasive procedures like transbronchial biopsy [66, 67]. Once 
a biopsy is obtained, it is evaluated using immunohistochemistry. The lungs are a 
common site of amyloid deposition, although not always symptomatic. There are 
three main kinds of pulmonary amyloidosis: nodular, diffuse, and tracheobronchial. 
Systemic amyloidosis is symptomatic, and often as a result of chronic inflammation.
7.1 Nodular pulmonary amyloidosis
Nodular amyloid deposits involving the lung are usually an incidentaloma on 
chest imaging and usually consist of AL light chain or mixed AL-AH light chain-
heavy chain [68, 69]. Nodular amyloidosis has been associated with mucosa associ-
ated lymphoid tissue (MALT) and Sjogren disease [68]. In a study of 49 individuals 
with nodular AL amyloidosis, surgical resection and systemic chemotherapy 
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were the major forms of treatment [64]. In fact, conservative excision in nodular 
AL amyloidosis presents with a great prognosis, although intervention is rarely 
required as a whole.
7.2 Diffuse alveolar amyloidosis
Presence of amyloid deposits on the alveolar walls and adjoining blood vessels 
signifies diffuse alveolar amyloidosis [70–72]. Since pulmonary impairment is not 
prominent in diffuse alveolar amyloidosis, it is often observed as a finding of post-
mortem studies [73]. Positron emission tomography using radiolabeled florbetapir 
is one of the modalities that can help identify the diffuse alveolar variant of amyloi-
dosis [74]. Diffuse alveolar amyloidosis has a progressive course of interstitial lung 
disease involving an infiltrative imaging pattern and dyspnea [75].
Diffuse alveolar amyloidosis is most commonly a manifestation of systemic AL 
amyloidosis, which is why treatment takes the form of targeting the underlying 
systemic amyloidosis. Burden reduction of free light chain is deemed to be central 
principle of treatment. Chemotherapy like low-dose Melphalan derived for multiple 
myeloma currently drives the treatment modalities used for diffuse alveolar amyloido-
sis [76–78]. Prednisolone is another medication used for treatment purposes. However, 
it is important to fashion treatment on a personalized basis based on patient needs. 
Pulmonary amyloidosis especially complicates the scenario when diffusion capacity 
reduces to less than 50%, although stem cell transplantation is an option in these cases 
[79]. Lung transplant is yet another option to treat isolated lung amyloidosis [80].
7.3 Laryngeal amyloidosis
Usually localized in nature, laryngeal amyloidosis is manifested by amyloid 
deposits superior to the glottis. The larynx is the most common location for isolated 
amyloid deposition in the head and neck, and symptomatically presents with stri-
dor, dyspnea, and hoarseness [81]. Larger lesions are often surgically removed with 
an endoscopic excision or laryngofissure [82, 83]. Smaller lesions can be treated 
with carbon dioxide laser evaporation [84, 85].
7.4 Tracheobronchial amyloidosis
Tracheobronchial amyloidosis is characterized by submucosal plaques with 
occasional involvement of the trachea and larynx [86, 87]. Cough, dyspnea, and 
hemoptysis are common manifestations, with tracheal and bronchial thickening and 
calcifications being diagnostic markers on CT [88, 89]. Stenting is also used to prevent 
airway collapse in an already compromised respiratory circuit. Although treatment 
modalities for tracheobronchial amyloidosis are limited, systemic chemotherapy is 
sometimes used [89]. Tracheobronchial involvement can be symptomatically treated 
with debridement, bronchoscopic resection, and external beam radiation [90, 91].
7.5 A peek into the future
Agents are being developed that aim to help stabilize amyloid in their native 
morphology and slow down or even halt fibril deposition. Glycosaminoglycans 
(GAG)-like molecules inhibitors and Secreted Aspartyl Proteinase (SAP)-binding 
inhibitors are currently being developed. GAG binding to amyloid enhances amy-
loid fibril deposition, while SAP potentiates amyloidosis [92, 93]. Like mentioned 
earlier, it is paramount to mold each treatment plan according to the recipient to 
best suit the patient’s needs and goals of care.
13
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Amyloidosis: Systems-Based Therapies
DOI: http://dx.doi.org/10.5772/intechopen.85201
Author details
Eileen Ly, Anu Stephen, Yasmeen Alhomsy, Asal Homayouni, Joshua Fisher, 
Kayla Sheehan, Prashanth Venkataraman, Quinto Gesiotto, Matthew Habib 
and Matthew Zabel*
College of Medicine, California Northstate University, Elk Grove, CA, USA
*Address all correspondence to: matthew.zabel9352@cnsu.edu
14
Amyloid Diseases
[1] Nienhuis HL, Bijzet J, Hazenberg BP.  
The prevalence and management 
of systemic amyloidosis in Western 
countries. Kidney Diseases. 
2016;2(1):10-19
[2] Quock TP, Yan T, Chang E, Guthrie S, 
Broder MS. Epidemiology of AL 
amyloidosis: A real-world study using 
US claims data. Blood Advances. 
2018;2(10):1046-1053
[3] Kyle R, Linos A, Beard C, Linke R, 
Gertz M, O’Fallon W, et al. Incidence 
and natural history of primary systemic 
amyloidosis in Olmsted County, 
Minnesota, 1950 through 1989. Blood. 
1992;79(7):1817-1822
[4] Pinney JH, Smith CJ, Taube JB, 
Lachmann HJ, Venner CP, Gibbs SD,  
et al. Systemic amyloidosis in 
England: An epidemiological study. 
British Journal of Haematology. 
2013;161(4):525-532
[5] de Asúa D, Costa R, Galván JM,  
Filigheddu MT, Trujillo D, Cadiñanos J.  
Systemic AA amyloidosis: 
Epidemiology, diagnosis, and 
management. Clinical Epidemiology. 
2014;6:369-377
[6] Hemminki K, Li X, Försti A, 
Sundquist J, Sundquist K. Incidence and 
survival in non-hereditary amyloidosis 
in Sweden. BMC Public Health. 
2012;12:974
[7] El-Jawahri A, Greer JA, Pirl WF, Park 
ER, Jackson VA, Back AL, et al. Effects 
of early integrated palliative care on 
caregivers of patients with lung and 
gastrointestinal cancer: A randomized 
clinical trial. The Oncologist. 
2017;22(12):1528-1534
[8] Tsukanov J, Fabbro ED. Palliative 
care and symptom management in 
amyloidosis: A review. Current Problems 
in Cancer. 2016;40(5-6):220-228
[9] Muliyala K, Varghese M. The 
complex relationship between 
depression and dementia. Annals 
of Indian Academy of Neurology. 
2010;13(Suppl 2):S69-S73
[10] Rapp M, Schnaider-Beeri M, 
Grossman H, Sano M, Perl D, Purohit D, 
et al. Increased hippocampal plaques 
and tangles in patients with Alzheimer 
disease with a lifetime history of 
major depression. Archives of General 
Psychiatry. 2006;63(2):161-167
[11] Ganguli M. Depression, cognitive 
impairment and dementia: Why 
should clinicians care about the web of 
causation? Indian Journal of Psychiatry. 
2009;51(Suppl 1):S29-S34
[12] Kim H, Kong E, Cheon E, Kim H, 
Koo B. Association between cerebral 
amyloid deposition and clinical factors 
including cognitive function in geriatric 
depression: Pilot study using amyloid. 
Clinical Psychopharmacology and 
Neuroscience. 2016;14(4):378-382
[13] Kantanen M, Kiuru-Enari S, 
Salonen O, Kaipainen M, Hokkanen 
L. Subtle neuropsychiatric and 
neurocognitive changes in hereditary 
gelsolin amyloidosis (AGel amyloidosis). 
Peer J. 2014;2:e493
[14] Bensamoun D, Guignard R, Furst A, 
Derreumaux A, Manera V,  
Darcourt J, et al. Associations 
between neuropsychiatric symptoms 
and cerebral amyloid deposition in 
cognitively impaired elderly people. 
Journal of Alzheimer's Disease. 
2016;49(2):387-398
[15] Said M, Johnson H, Nonyane B, 
Deloria-Knoll M, O’Brien K, Andreo F,  
et al. Estimating the burden of 
pneumococcal pneumonia among 
adults: a systematic review and meta-
analysis of diagnostic techniques. 
PLoS One. 2013;8(4):e60273
References
15
Amyloidosis: Systems-Based Therapies
DOI: http://dx.doi.org/10.5772/intechopen.85201
[16] Bergesio F, Ciciani A, Manganaro M, 
Palladini G, Santostefano M, 
Brugnano R, et al. Renal involvement 
in systemic amyloidosis: an Italian 
collaborative study on survival and 
renal outcome. Nephrology Dialysis 
Transplantation. 2008;23(3):941-51
[17] Mazdak A, Wallace W, Palma-Diaz M. 
Amyloid nephropathy. Clinical Kidney 
Journal. Apr 2014;7(2):97-106
[18] Seldin D, inner OB, Quillen K, 
Finn K. Relapse rate and long-term 
survival of AL amyloidosis patients 
treated with high-dose melphalan and 
autologous stem cell transplantation 
(HDM/SCT). Blood. 2006;108:3094
[19] Skinner M, Sanchorawala V, 
Seldin D, Dember L, Falk R, Berk J, 
et al. High-dose melphalan and 
autologous stem-cell transplantation 
in patients with AL amyloidosis: An 
8-year study. Amyloid and Amyloidosis. 
2004;140(2):85-93
[20] Seldin M, Shigeta R, Villoslada P, 
Selmi C, Tuomilehto J, Silva G, et al. 
European Population Substructure: 
Clustering of Northern and Southern 
Populations. PLoS Genetics. 2006; 
2(9):e143
[21] Leung N, Griffin DA, Haugen E,  
Gloor J, Schwab T, et al. Living donor 
kidney and autologous stem cell 
transplantation for primary systemic 
amyloidosis (AL) with predominant 
renal involvement. American Journal of 
Transplantation. 2005;5(7):1660-1670
[22] Wechalekar A, Gillmore J, Bird J,  
Cavenagh J, Hawkins S, Kazmi M, 
et al. Guidelines on the management 
of AL amyloidosis. British Journal of 
Haematology. 2015;168(2):186-206
[23] Palladini G, Perfetti V, Obici L, 
Caccialanza R, Semino A, Adami F, 
et al. Association of melphalan and 
high-dose dexamethasone is effective 
and well tolerated in patients with 
AL (primary) amyloidosis who are 
ineligible for stem cell transplantation. 
Blood. 2004;103(8):2936-2938
[24] Ozen S. Renal amyloidosis in 
familial mediterranean fever. Kidney 
International. 2004;65(3):1118-1127
[25] Elkayam O, Hawkins P, Lachmann 
H, Yaron M, Caspi D. Rapid and 
complete resolution of proteinuria 
due to renal amyloidosis in a patient 
with rheumatoid arthritis treated with 
infliximab. Arthritis and Rheumatism. 
2002;46(10):2571-2573
[26] Yan DS, Zhu H, Zhu A, Golabek A,  
Du H, Roher A, et al. Receptor-
dependent cell stress and amyloid 
accumulation in systemic amyloidosis. 
Nature Medicine. 2000;6(6):643-651
[27] Dember L, Hawkins P, Hazenberg B, 
Gorevic P, Merlini G, Butrimiene I, 
et al. Eprodisate for the treatment of 
renal disease in AA amyloidosis. NEJM. 
2007;356(23):2349-2360
[28] Rumjon A, Coats T, Javaid M.  
Review of eprodisate for the treatment 
of renal disease in AA amyloidosis. 
International Journal of Nephrology and 
Renovascular Disease. 2012;5:37-43
[29] Guillaume B, N Straetmans N, 
Jadoul M, Cosyns J, Ferrant A. 
Allogeneic bone marrow transplantation 
for AL. Bone Marrow Transplantation. 
1997;20:907-908
[30] Gursu M, Yelken B, Caliskan Y, 
Kazancioglu R, Yazici H, Kilicaslan I, 
et al. Outcome of patients with 
amyloidosis after renal transplantation: 
a single-center experience. International 
Journal of Artificial Organs. 2012; 
35(6):444-449
[31] Moreau P, Avet-Loiseau H, Facon T,  
Attal M, Tiab M, Hulin C, et al. 
Bortezomib plus dexamethasone 
versus reduced-dose bortezomib, 
thalidomide plus dexamethasone as 
Amyloid Diseases
16
induction treatment prior to autologous 
stem cell transplantation in newly 
diagnosed multiple myeloma. Blood. 
2011;118(22):5752-5758
[32] Kumar S, Dispenzieri A, Lacy M,  
Gertz M, Buadi F, Pandey S, et al. 
Continued improvement in survival 
in multiple myeloma: Changes 
in early mortality and outcomes 
in older patients. Leukemia. 
2014;28(5):1122-1128
[33] Brenner H, Gondos A, Pulte D.  
Recent major improvement in long-
term survival of younger patients 
with multiple myeloma. Blood. 
2008;111(5):2521-2526
[34] Bringhen S, Milan A, Ferri C, 
Wäsch R, Gay F, Larocca A, et al. 
Cardiovascular adverse events in 
modern myeloma therapy–incidence 
and risks. A review from the European 
myeloma network (EMN) and Italian 
Society of Arterial Hypertension. 
Haematologica. 2018;103(9):1422-1432
[35] Niesvizky R, Flinn I, Rifkin R, 
Gabrail N, Charu V, Clowney B, et al. 
Community-based phase IIIB trial of 
three UPFRONT bortezomib-based 
myeloma regimens. Journal of Clinical 
Oncology. 2015;33(33):3921-3929
[36] Cerrato C, Raimondo DF, Paoli DL,  
Spada S, Patriarca F, Crippa C, et al. 
Maintenance in myeloma patients 
achieving complete response after 
upfront therapy: A pooled analysis. 
Journal of Cancer Research and Clinical 
Oncology. 2018;144(7):1357-1366
[37] Madan S, Dispenzieri A, Lacy M,  
Buadi F, Hayman S, Zeldenrust S, 
et al. Clinical features and treatment 
response of light chain (AL) amyloidosis 
diagnosed in patients with previous 
diagnosis of multiple myeloma. Mayo 
Clinic Proceedings. 2010;85(3):232-238
[38] Kastritis E, Anagnostopoulos A, 
Roussou M, Toumanidis S, Pamboukas 
C, et al. Treatment of light chain (AL) 
amyloidosis with the combination 
of bortezomib and dexamethasone. 
Haematologica. 2007;92(10):1351-1358
[39] Chaulagain C, Comenzo R. How we 
treat systemic light-chain amyloidosis. 
Clinical Advances in Hematology & 
Oncology. 2015;13(5):315-324
[40] Reece D, Hegenbart U, 
Sanchorawala V, Merlini G, Paladini G,  
Blade J, et al. Long-term follow-up 
from a phase 1/2 study of single-
agent bortezomib in relapsed 
systemic AL amyloidosis. Blood. 
2014;124(16):2498-2506
[41] Reece D, Hegenbart U, 
Sanchorawala V, Merlini G, Paladini G,  
Blade J, et al. Efficacy and safety 
of once-weekly and twice-weekly 
bortezomib in patients with 
relapsed systemic AL amyloidosis: 
Results of a phase 1/2 study. Blood. 
2011;118(4):865-873
[42] Kastritis E, Leleu X, Arnulf B,  
Zamagni E, Cibeira M, et al. A 
randomized phase III trial of melphalan 
and dexamethasone (MDex) 
versus bortezomib, melphalan and 
dexamethasone (BMDex) for untreated 
patients. Blood. 2016;128:646
[43] Lasek-Bal A, Holecki M, Czapska A, 
Karuga A, Dulawa J. Primary clinical 
manifestation of systemic amyloidosis 
in the central nervous system. Polskie 
Archiwum Medycyny Wewnętrznej. 
2014;124(3):138-139
[44] Adav S, Gallart-Palau X, Tan K, 
Lim S, Tam J, et al. Dementia-linked 
amyloidosis is associated with brain 
protein deamidation as revealed by 
proteomic profiling of human brain 
tissues. Molecular Brain. 2016;9(20):1-10
[45] Banerjee G, Carare R, Cardonnier C, 
Greenberg S, Schneider J, et al. The 
increasing impact of cerebral amyloid 
angiopathy: Essential new insights for 
17
Amyloidosis: Systems-Based Therapies
DOI: http://dx.doi.org/10.5772/intechopen.85201
clinical practice. Journal of Neurology, 
Neurosurgery, and Psychiatry. 
2017;88(11):982-994
[46] Shin SC, Robinson-Papp J. Amyloid 
neuropathies. Mount Sinai Journal of 
Medicine: A Journal of Translational 
and Personalized Medicine. 
2012;79(6):733-748
[47] Bard F, Cannon C, Barbour R, 
Burke R, medicine GD. Peripherally 
administered antibodies against amyloid 
β-peptide enter the central nervous 
system and reduce pathology in a mouse 
model of alzheimer disease. Nature. 
2000;6:916-919
[48] Van Dyck C. Anti-amyloid-β 
monoclonal antibodies for Alzheimer’s 
disease: Pitfalls and promise. Biological 
Psychiatry. 2018;83(4):311-319
[49] Coelho T, Adams D, Silva A, 
Lozeron P, Hawkins P, Mant T, et al. 
Safety and efficacy of RNAi therapy 
for transthyretin amyloidosis. NEJM. 
2013;369:819-829
[50] Sekijima Y, Yazaki M, Oguchi K, 
Ezawa N, Yoshinaga T, Yamada M, 
et al. Cerebral amyloid angiopathy in 
posttransplant patients with hereditary 
ATTR amyloidosis. Neurology. 
2016;87:1-9
[51] Suhr OB, Herlenius G, Friman S,  
Ericzon B. Liver transplantation for 
hereditary transthyretin amyloidosis. 
Liver Transplantation. 2000;6(3):263-276
[52] Merlini G, Ascari E, Amboldi N, 
Bellotti V, Arbustini E, Perfetti V, et al. 
Interaction of the anthracycline 4′-iodo-
4′-deoxydoxorubicin with amyloid 
fibrils: Inhibition of amyloidogenesis. 
PNAS. 1995;92(7):2959-2963
[53] Cardoso I, Saraiva M. Doxycycline 
disrupts transthyretin amyloid: 
Evidence from studies in a FAP 
transgenic mice model. The FASEB 
Journal. 2006;20(2):234-239
[54] Obici L, Cortese A, Lozza A, 
Lucchetti J, Amyloid GM. Doxycycline 
plus tauroursodeoxycholic acid for 
transthyretin amyloidosis: a phase 
II Study. Amyloid: the international 
journal of experimental and clinical 
investigation. 2012;19(1):34-36
[55] Adams D, Gonzalez-Duarte A, 
O’Riordan WD, Yang C-C, Ueda M, 
Kristen AV, et al. Patisiran, an RNAi 
therapeutic, for hereditary transthyretin 
amyloidosis. New England Journal of 
Medicine. 2018;379(1):11-21
[56] Benson MD, Waddington-Cruz M,  
Berk JL, Polydefkis M, Dyck PJ, Wang 
AK, et al. Inotersen treatment for 
patients with hereditary transthyretin 
amyloidosis. New England Journal of 
Medicine. 2018;379(1):22-31
[57] Donnelly JP, Hanna M. Cardiac 
amyloidosis: An update on diagnosis and 
treatment. Cleveland Clinic Journal of 
Medicine. 2017;84(12 Suppl 3):12-26
[58] Maurer MS, Schwartz JH, 
Gundapaneni B, Elliott PM, Merlini G,  
Waddington-Cruz M, et al. 
Tafamidis treatment for patients with 
transthyretin amyloid cardiomyopathy. 
New England Journal of Medicine. 
2018;379(11):1007-1016
[59] Mesquita E, Jorge A, Junior C, de 
Andrade T. Cardiac amyloidosis and its 
new clinical phenotype: Heart failure 
with preserved ejection fraction. 
Arquivos Brasileiros de Cardiologia. 
2017;109(1):71-80
[60] Gertz MA, Falk RH, Skinner M, 
Cohen AS, Kyle RA. Worsening of 
congestive heart failure in amyloid heart 
disease treated by calcium channel-
blocking agents. The American Journal 
of Cardiology. 1985;55(13):1645
[61] Pollak A, Falk RH. Left ventricular 
systolic dysfunction precipitated by 
verapamil in cardiac amyloidosis. Chest. 
1993;104(2):618-620
Amyloid Diseases
18
[62] Patel K, Hawkins P. Cardiac 
amyloidosis: Where are we today? 
Journal of Internal Medicine. 
2015;278(2):126-144
[63] Sipe JD, Benson MD, Buxbaum 
JN, Ikeda S, Merlini G, Saraiva MJ, 
et al. Amyloid fibril proteins and 
amyloidosis: Chemical identification 
and clinical classification International 
Society of Amyloidosis 2016 
nomenclature guidelines. Amyloid. 
2016;4:1-5
[64] Milani P, Basset M, Russo F, Foli A,  
Palladini G, Merlini G. The lung in 
amyloidosis. European Respiratory 
Review. 2017;26(145):170046
[65] Riek R, Eisenberg DS. The 
activities of amyloids from a 
structural perspective. Nature. 
2016;539(7628):227-235
[66] Foli A, Palladini G, Caporali R, 
Verga L, Morbini P, Obici L, et al. The 
role of minor salivary gland patients. 
Amyloid. 2011;18(sup1):80-82
[67] de Larrea C, Verga L, Morbini P, 
Klersy C, Lavatelli F, Foli A, et al. A 
practical approach to the diagnosis 
of systemic amyloidoses. Blood. 
2015;125(14):2239-2244
[68] Grogg KL, Aubry M-C, Vrana JA, 
Theis JD, Dogan A. Nodular pulmonary 
amyloidosis is characterized by localized 
immunoglobulin deposition and is 
frequently associated with an indolent 
B-cell lymphoproliferative disorder. The 
American Journal of Surgical Pathology. 
2013;37(3):406
[69] Kaplan B, Martin BM, Boykov O,  
Gal R, Pras M, Shechtman I, et al. 
Co-deposition of amyloidogenic 
immunoglobulin light and heavy chains 
in localized pulmonary amyloidosis. 
Virchows Archiv. 2005;447(4):756-761
[70] Hui A, Koss M, Hochholzer L, 
Wehunt W. Amyloidosis presenting 
in the lower respiratory tract. 
Clinicopathologic, radiologic, 
immunohistochemical, and 
histochemical studies on 48 cases. 
Archives of Pathology & Laboratory 
Medicine. 1986;110(3):212-218
[71] Nivas R, Singh N, Gupta K, Gupta 
D. Pulmonary amyloidosis in Sjogren’s 
syndrome: A case report and systematic 
review of the literature. Respirology. 
2010;15(5):860-866
[72] BoydKing A, Sharma O, Stevenson 
K. Localized interstitial pulmonary 
amyloid: A case report and review 
of the literature. Current Opinion in 
Pulmonary Medicine. 2009;15(5):517
[73] Smith R, Hutchins GM, Moore GW, 
Humphrey RL. Type and distribution of 
pulmonary parenchymal and vascular 
amyloid correlation with cardiac 
amyloidosis. The American Journal of 
Medicine. 1979;66(1):96-104
[74] Park M-A, Padera RF, Belanger 
A, Dubey S, Hwang DH, Veeranna 
V, et al. 18F-Florbetapir binds 
specifically to myocardial light chain 
and transthyretin amyloid deposits. 
Circulation. Cardiovascular Imaging. 
2018;8(8):e002954
[75] Ohdama S, Akagawa S, Matsubara 
O, Yoshizawa Y. Primary diffuse alveolar 
septal amyloidosis with multiple cysts 
and calcification. European Respiratory 
Journal. 1996;9(7):1569-1571
[76] Kyle RA, Gertz MA, Greipp PR,  
Witzig TE, Lust JA, Lacy MQ , et al. 
A trial of three regimens for primary 
amyloidosis: Colchicine alone, 
melphalan and prednisone, and 
melphalan, prednisone, and colchicine. 
New England Journal of Medicine. 
1997;336(17):1202-1207
[77] Comenzo R, Vosburgh E, Falk R, 
Sanchorawala V, Reisinger J, Dubrey S,  
et al. Dose-intensive melphalan 
with blood stem-cell support for 
19
Amyloidosis: Systems-Based Therapies
DOI: http://dx.doi.org/10.5772/intechopen.85201
the treatment of AL (amyloid light-
chain) amyloidosis: Survival and 
responses in 25 patients. Blood. 
1998;91(10):3662-3670
[78] Gillmore JD, Davies J, Iqbal A, 
Madhoo S, Russell NH, Hawkins PN.  
Allogeneic bone marrow transplantation 
for systemic AL amyloidosis. 
British Journal of Haematology. 
1998;100(1):226-228
[79] Gertz M, Lacy M, Dispenzieri A, 
Kumar S, Dingli D, Leung N, et al. 
Refinement in patient selection to 
reduce treatment-related mortality from 
autologous stem cell transplantation 
in amyloidosis. Bone Marrow 
Transplantation. 2013;48(4):557
[80] Ware L, Keith F, Gordon R, 
Ries C, Seitz R, Gold W, et al. Lung 
transplantation for pulmonary 
amyloidosis: A case report. The Journal 
of Heart and Lung Transplantation. 
1998;17(11):1129-1132
[81] Lewis JE, Olsen KD, 
Kurtin PJ, Kyle RA. Laryngeal 
amyloidosis: A clinicopathologic 
and Immunohistochemical review. 
Otolaryngology–Head and Neck 
Surgery. 1991;106(4):372-377
[82] Darcy F. Localized amyloidosis of 
the larynx. The Journal of Laryngology 
& Otology. 1972;86(9):929-931
[83] Walker PA, Courey MS, Ossoff RH.  
Staged endoscopic treatment of 
laryngeal amyloidosis. Otolaryngology–
Head and Neck Surgery. 
1996;114(6):801-805
[84] Finn DG, Farmer JC. Management 
of amyloidosis of the larynx and 
trachea. Archives of Otolaryngology. 
1982;108(1):54-56
[85] Mcilwain J, Shepperd H. Laser 
treatment of primary amyloidosis of the 
larynx. The Journal of Laryngology & 
Otology. 1986;100(9):1079-1080
[86] Utz J, Swensen S, Gertz M.  
Pulmonary amyloidosis. The Mayo clinic 
experience from 1980 to 1993. Annals of 
Internal Medicine. 1996;124(4):407-413
[87] Graham C, Stern E, Finkbeiner W,  
Webb W. High-resolution CT 
appearance of diffuse alveolar septal 
amyloidosis. AJR American Journal of 
Roentgenology. 1992;158(2):265-267
[88] Crestani B, Monnier A, 
Kambouchner M, Battesti J, Reynaud P,  
Valeyre D. Tracheobronchial 
amyloidosis with hilar 
lymphadenopathy associated with a 
serum monoclonal immunoglobulin. 
The European Respiratory Journal. 
1993;6(10):1569-1571
[89] O’Regan A, Fenlon HM, Beamis JF,  
Steele MP, Skinner M, Berk JL.  
Tracheobronchial amyloidosis: The 
Boston University experience from 1984 
to 1999. Medicine. 2000;79(2):69
[90] Monroe AT, Walia R, Zlotecki RA,  
Jantz MA. Tracheobronchial 
amyloidosis a case report of successful 
treatment with external beam radiation 
therapy. Chest. 2004;125(2):784-789
[91] Neben-Wittich MA, Foote RL, Kalra 
S. External beam radiation therapy for 
tracheobronchial amyloidosis. Chest. 
2007;132(1):262-267
[92] Botto M, Hawkins PN, Bickerstaff 
M, Herbert J, Bygrave AE, Mcbride 
A, et al. Amyloid deposition is 
delayed in mice with targeted 
deletion of the serum amyloid P 
component gene. Nature Medicine. 
1997;3(8):nm0897-nm0855
[93] Kisilevsky R, Lemieux LJ, Fraser PE, 
Kong X, Hultin PG, Szarek WA.  
Arresting amyloidosis in vivo using 
small-molecule anionic sulphonates or 
sulphates: Implications for Alzheimer’s 
disease. Nature Medicine. 1995;1(2):143
